Synexus, the UK-based patient recruitment and clinical trial management business acquired last December by private equity firm Lyceum Capital, boosted its turnover by more than 50% to over US$30 million in the first half of this year.

Even more gratifyingly, noted chief executive officer Michael Fort, the company’s forward order book has tripled. Moreover, there are plans for further expansion, with over five new hubsites – the network of dedicated sites that Synexus uses to recruit for and run Phase II-IV clinical trials – over the next nine months.

Before yielding to a private equity buyout, Synexus had been plagued by delayed start dates for contracted clinical trials, which cut into its turnover and profit while the company’s share price plummeted.

Now it appears to be on much firmer ground. In April the company said it had reached a milestone of more than 10,000 patients enrolled in late-stage studies across its 14 hub sites in six countries. And according to Fort, Synexus is “well on our way to doubling our capacity to 25,000 patients”.